Next Article in Journal
Changes in Proteolysis in Fermented Milk Produced by Streptococcus thermophilus in Co-Culture with Lactobacillus plantarum or Bifidobacterium animalis subsp. lactis During Refrigerated Storage
Previous Article in Journal
Antimalarial Properties of Dunnione Derivatives as NQO2 Substrates
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 24
Issue 20
10.3390/molecules24203698
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

The Effects of a Novel Series of KTTKS Analogues on Cytotoxicity and Proteolytic Activity

by
Urszula Tałałaj
1,
Paulina Uścinowicz
1,
Irena Bruzgo
1,
Arkadiusz Surażyński
2,
Ilona Zaręba
2 and
Agnieszka Markowska
1,*
1
Department of Organic Chemistry, Medical University of Białystok, Białystok 15-089, Poland
2
Department of Medicinal Chemistry, Medical University of Białystok, Białystok 15-089, Poland
*
Author to whom correspondence should be addressed.
Molecules 2019, 24(20), 3698; https://doi.org/10.3390/molecules24203698
Submission received: 26 August 2019 / Revised: 8 October 2019 / Accepted: 11 October 2019 / Published: 15 October 2019
(This article belongs to the Section Medicinal Chemistry)
Browse Figures
Versions Notes

Abstract

:
KTTKS is a matrikine that originates from the proteolytic hydrolysis of collagen. This peptide stimulates ECM production and types I and III collagen expression in vitro. A more stable form of KTTKS is pal-KTTKS, known as Matrixyl® or palmitoyl pentapeptide-3. A series of novel pentapeptides, analogues of KTTKS with the general formula X-KTTKS-OH(NH2), where X = acetyl, lipoyl, palmitoyl residues, was designed and synthesized. Their effect on amidolytic activity of urokinase, thrombin, trypsin, plasmin, t-PA, and kallikrein were tested. Cytotoxic tests on fibroblasts, as well as collagen and DNA biosynthesis tests for selected peptides, were also carried out. The test results showed that the most active plasmin inhibitors were palmitoyl peptides, whether in acid or amide form. No biological effects of lysine modification to arginine in the synthesized peptides were found. None of the synthesized peptides was not cytotoxic on fibroblasts, and three of them showed cell growth. These three compounds showed no concentration-activity relationship in the collagen and DNA biosynthesis assays.

1. Introduction

Aging is a natural process connected with decreased metabolic activity in cells and poor regenerative abilities of the human body [1,2]. Much effort is directed nowadays to the subject of skin aging largely due to the belief that a person’s image confirms their attractiveness and credibility. There are numerous products on the market, collectively referred to as “cosmeceuticals”, whose aim is to remedy skin aging processes such as dry skin or the appearance of wrinkles. The first anti-aging (anti-wrinkle) cosmeceuticals, introduced in the early 1990s, were fruit acids, which improve skin appearance through peeling and moisturizing. The next generations of anti-wrinkle products were retinol and its derivatives, used in the treatment of acne lesions. In addition, they smoothen wrinkles and help remove skin discolorations. The 21st century marks the appearance of lipopeptide technologies.
The concept of using peptides as cosmetics was based on a group of natural compounds called matrikines [3,4,5,6], whose name is a compound of the terms “extracellular matrix” + “cytokines”. An extracellular matrix (ECM) contains numerous extracellular proteins and glycosaminoglycans undergoing limited proteolysis, resulting in the release of biologically active fragments whose activity differs from that of full-length molecules [3,7]. This breakdown is caused by specific hydrolytic enzymes: Collagenases, elastases, hyaluronidases, or cathepsins. The process of hydrolysis in question is not accidental, as would have been the case with chemical acid hydrolysis, due to the release of peptides acting as endogenous regulators of many physiological and pathological processes [8]. Matrikines are mostly short, usually 3-8-amino acid long, but 700-amino-acid-long ones also do occur [9]. Examples of collagen-derived matrikines are endostatin, endotrophin, endorepellin, or tumstatin [10]. Peptides from the laminin α4 and α5 chains show antibacterial properties against E. coli and S. aureus [11]. Endostatin regulates adipose tissue weight in a mouse model of obesity [12]. Elastin peptides regulate insulin resistance in mice [13]. Endotrophin, a product of the breakdown of collagen VI released by adipocytes, may play a role in obesity-related cancers [14,15]. Endostatin and anastellin have the ability to form amyloid fibres and may contribute to the formation of amyloid deposits, causing neurodegenerative diseases [16,17].
The role of matrikines in the skin was described in 2005 by Tran [8]. ECM fragments such as hyaluronan oligosaccharides, laminin peptides A13 and C16, the LG4 domain of laminin, and tripeptide GHK regulate wound healing [18,19]. Tripeptide GHK itself, as well as its inclusion in collagen film preparations may stimulate wound healing through the increase of collagen synthesis by fibroblasts. Another peptide, i.e., peptide VVPQ derived from elastin, has a mitogenic effect on skin fibroblasts [20]. KKLRIKSKE-sequence peptides of the LG4 domain of laminin a3 contribute to epidermis repair as they induce adhesion and keratinocyte migration. Angiogenic peptides from the a1 (A13) chain and the c1 (C16) chain of laminin stimulate wound healing by stimulating fibroblast migration and reducing the expression of pro and active forms of MMP2 in fibroblasts [21,22]. Skin condition is also improved by hyaluronan fragments, depending on their size. The high molecular mass of hyaluronan (1000–1400 kDa) or its fragments with a low molecular mass (5–20 kDa) have no healing properties, whereas medium-sized fragments (100–300 kDa) enable faster wound closure [23,24].
KTTKS, lysine-threonine-threonine-lysine-serine is a matrikine originating from proteolytic hydrolysis of collagen [25,26]. This peptide stimulates ECM production as well as fibronectin and type I and III collagen expression in vitro. It also stabilizes mRNA, which enables TGF-β synthesis. A palmitoyl, a more stable form of KTTKS (pal-KTTKS), also known as Matrixyl® or palmitoyl pentapeptide-3, is able to penetrate the stratum corneum and enhance collagen I production by fibroblasts in vitro [27]. Pal-KTTKS also significantly increases procollagen production and regulates hyaluronic acid synthesis by human fibroblasts in vitro. The clinical result of an oil-in-water moisturizing cream containing pal-KTTKS was assessed in a double-blind randomized placebo-controlled trial in 94 healthy Caucasian females with face wrinkles. After administration of pal-KTTKS twice daily for 8 and 12 weeks, the length of wrinkles, age spots, and skin texture were markedly improved and reduced in subjects using the cream containing pal-KTTKS compared to the placebo cream [25].
Skin aging is a natural, progressive process involving a reduction in its biological activity, a slowdown of its regenerative processes, and especially dryness [2,28,29]. Excessive activation of the system of plasminogen activation, i.e., a group of serine enzymes, was found in dry skin [30,31]. In normal skin plasmin is only found in the basement membrane of the epidermis, whereas in the case of dry skin, it is found throughout the whole epidermis [32,33]. Urokinase plasminogen activator (uPA) is also present in the stratum corneum of the epidermis, as confirmed in tests of fibrinolytic activity in the stratum corneum of the epidermis, which was counteracted by the addition of anti-urokinase antibody [34,35]. Urokinase activation in SC was confirmed in tests in vitro, in which a urokinase precursor (pro-uPA) became active after incubation with the insoluble component of homogenate SC. These results show that the urokinase-type plasminogen activator is activated in SC after breaking the barrier, which may activate the plasminogen/plasmin system in the epidermis [36]. A positive correlation between enzymes of the plasminogen system and transepidermal water loss was also found (TEWL) [37].
It has been shown that it is possible to inhibit the activity of the enzymes in question in the skin. A well-known antifibrinolytic, i.e., trans-4-(aminomethyl)cyclohexanecarboxylic acid (AMCHA, TXA), and its methylamide both have an inhibitory effect on plasmin, increasing the regeneration of the barrier function of the stratum corneum of the epidermis after tests with the use of the tape strippings method, exposed to acetone and dodecyl sulphate, preventing epidermis hyperplasia and alleviating conditions that cause skin dryness [38,39,40,41]. Unfortunately, fibrinolytic activity inhibition does not result in the inhibition of the active centre of plasmin or urokinase. AMCHA does not bind with the active site of plasmin, with kringle domains on plasmin and/or plasminogen, to be precise, thus preventing tPA/uPA-induced activation of plasminogen to plasmin. Voegeli et al. described a competitive and reversible plasmin and urokinase inhibitor, benzylsulfonyl-d-Ser-homoPhe- (4-amidinobenzylamide) (BSFAB), with the following values: Ki 29 nM for plasmin and 25 nM for urokinase [42]. Moreover, BSFAB was shown to be a selective inhibitor, as it did not inhibit other key proteases present in SC, such as tryptase, kallikrein 5 and 7, or neutrophil elastase. Kallikreins are enzymes necessary for peeling, which is why BSFAB does not have an impact on the process of peeling and does not induce dry skin.
By combining the application of cosmetic peptides in cosmetics for dry and aging skin with inhibited serine protease activity, enzymatic, cytotoxic, collagen, and DNA biosynthesis tests on fibroblasts in vitro of 30 new peptides were planned, synthesized, and performed. The synthesis was based on the following stem sequence: -Lys-Thr-Thr-Lys-Ser-. The purpose of the modifications introduced to the compound in question was to find the structure-activity relationship of plasmin and urokinase, i.e., the inhibitors. Moreover, 2 basic peptides were synthesized: KTTKS and pal-KTTKS, which constitute the standards used for the tests. N-terminal groups, i.e., acetyl, palmitic, and lipoic, were introduced into the molecules; certain peptide sequences were also modified by changing lysine into arginine. In order to obtain the designed peptides, chemical synthesis on a solid medium, also called solid-phase synthesis, was used. All the obtained peptides were characterized using retention time, while mass of the compounds was confirmed with the use of mass spectrometry.
Biological tests consisted of an assessment of antiamidolytic activity against enzymes from the serine protease group, i.e., plasmin, uPA (urokinase type plasminogen activator), thrombin, t-PA (tissue type plasminogen activator), trypsin, kallikrein, and chymotrypsin. In addition, the influence of all the obtained compounds on fibroblast survival, as well as selected peptides for collagen and DNA biosynthesis, was verified.

2. Results

2.1. Peptide Synthesis

Thirty new and two previously known (KTTKS-OH and Pal-KTTKS-OH) peptides were obtained with satisfactory yields, ranging from 42 to 68%, by solid phase peptide synthesis. Two polymer media were used for the synthesis. Peptides containing the acidic group were synthesized on a 2-chlorotrityl linker, whereas peptides in the form of amides– on a Rink Amide polymer with a 4-[(2,4-dimethoxyphenyl)(Fmoc-amino)methyl]phenoxyacetic linker. Introduction of N-terminal fragments of peptides was performed: with the palmitoyl chloride in the presence of a base method in the case of the palmitoyl group, the classical amino acid coupling method in the case of lipoic acid, and with 1-acetylimidazole in the case of acetyl residue. Peptides were purified by semi-preparative HPLC whereas the retention time shown in Table S1 was determined using an analytical column. Mass spectrometry confirmed mass identity in relation to the designed peptides. The sequences and physicochemical parameters of the synthesized peptides 1–32 are also presented in Table S1

2.2. Enzymatic Investigations

Peptides that demonstrate activity blocking enzymes cause inhibition of hydrolysis of the synthetic chromogenic substrate for the enzyme. This is observed in the form of a decrease in the concentration of p-nitroaniline released from the synthetic substrates. The tested compounds did not affect trypsin, kallikrein, t-PA, and chymotrypsin activity. The amidolytic activity results of plasmin, urokinase, and thrombin for the synthesized peptides are presented in Table 1.
As IC50 values differ by several orders of magnitude, in order to present the results in the form of figures, they were converted into -logIC50. The values are presented in Table 2 and Figure 1.
Out of all the 32 designed compounds (Table 1 and Table 2 and Table S1, Figure 1), all N-palmitic peptides, i.e., 4, 8, 12, 16, 20, 24, 28, and 32, and both C-terminal acids and amides, turned out to be the most effective inhibitors of the tested enzymes. An analysis of the results shows that the most effective peptides that inhibit the activity of all three enzymes at a level above 90% are 20 Pal-Arg-Thr-Thr-Arg-Ser-OH and 28 Pal-Arg-Thr-Thr-Lys-Ser-OH.
In the case of plasmin, the greatest inhibition by palmitic peptides with micromole IC50 values was observed in the case of the most active peptide 8 Pal-KTTKS-NH2, 0.21 μM, to 0.89 μM for peptide 16 Pal-KTTRS-NH2 (Figure 1). The other peptides exhibited similar activity, with millimole IC50 inhibition values: from 0.24 mM in the case of Lip-KTTRS-OH (11) to 9.08 mM for Ac-RTTRS-NH2 (22, Table 1).
In the case of urokinase, peptides in the form of C-terminal acid turned out to be the most active. The most active were N-palmitic peptides Pal-Arg-Thr-Thr-Lys-Ser-OH (4), Pal-Lys-Thr-Thr-Arg-Ser-OH (12), Pal-Arg-Thr-Thr-Arg-Ser-OH (20), and Pal-Arg-Thr-Thr-Lys- Ser-OH (28, Figure 1). The calculated IC50 values for compounds 4, 12, 20, and 28 are 0.00086, 0.0008, 0.00049, and 0.00048 mM, respectively (Table 1).
Thrombin activity inhibition was exhibited by N-palmitic peptides Pal-Lys-Thr-Thr-Arg- Ser-OH (12), Pal-Arg-Thr-Thr-Arg-Ser-OH (20), and Pal-Arg-Thr-Thr-Lys-Ser-OH (28). The calculated IC50 values for compounds 12, 20, and 28 are 0.012, 0.03, and 0,0021 mM, respectively (Table 1).

2.3. Viability of Fibroblast Cells

Viability of fibroblast cells was examined with the use of the MTT assay. MTT, a yellow tetrazole, is reduced to purple formazan only in living cells. Absorbance of the coloured solution was measured by a spectrophotometer. The values are presented in Table 3 and Figure 2.
None of the synthesized compounds exhibited cytotoxicity towards fibroblasts (Figure 2 and Table 3). Peptides H-Lys-Thr-Thr-Arg-Ser-NH2 (13, blue line, Figure 2), Ac-Lys-Thr-Thr-Arg- Ser-NH2 (14, orange line, Figure 2), and Ac-Arg-Thr-Thr-Lys-Ser-OH (26, green line, Figure 2) exhibited cell growth effects.

2.4. DNA and Collagen Biosynthesis

Due to the fact that of those in the synthesized group, only peptides 13, 14 and 26 showed proliferative effect on fibroblasts in the MTT test, only those compounds were investigated in DNA and collagen biosynthesis.
In the radioactive method of DNA measurement in the liquid sample, the radioactive activity of the sample was measured. This technique involves mixing a radioactive material with a scintillation fluid/liquid (which contains a scintillator), resulting in photon emission. This emission is counted by a suitable detector. The values are presented in Table 4 and Figure 3.
In collagen biosynthesis assays cells were counted in a haemocytometer and incorporation of a radioactive precursor 5[3H]-proline into collagen was measured. Total protein synthesis was calculated from the sum of radioactivity of collagenase-resistant proteins and collagen digest. The values are presented in Table 5 and Figure 4.
None of the synthesized compounds exhibited cytotoxicity towards fibroblasts (Figure 2 and Table 3). Peptides H-Lys-Thr-Thr-Arg-Ser-NH2 (13, blue line, Figure 2), Ac-Lys-Thr-Thr-Arg- Ser-NH2 (14, orange line, Figure 2), and Ac-Arg-Thr-Thr-Lys-Ser-OH (26, green line, Figure 2) exhibited the effect of cell growth. In the case of these compounds, their influence of collagen (Table 5 and Figure 4) and DNA (Table 4 and Figure 3) biosynthesis were tested. In the case of DNA biosynthesis, no relationship with the concentration of the tested peptides was noticed; an increase in DNA synthesis was observed, however, in the case of compound 14, both at the minimum concentration of 10 μM and at the maximum concentration of 100 μM. In the case of peptide 26, increased DNA synthesis was observed at all concentrations. In the case of collagen biosynthesis, a significant increase was noticed, as high as up to approx. 160% for all the tested peptides, but there was no direct relationship with concentration.

3. Discussion

Human skin changes over time, throughout a person’s whole life. The formation of wrinkles is considered the most distinctive and the most common symptom of skin aging. Collagen is one of the most degrading proteins of the skin and its degradation is an important factor that affects skin aging. Degradation of collagen and other extracellular matrix (EM) components may also be associated with an increase in the damaging enzymes, such as plasmin and matrix metalloproteinase (MMP), which degrade laminin 332 and type IV and VII collagens [43].
The structure-activity relationships of 32 peptides in the following groups: C-terminal acids, C-terminal amides, peptides with a free N-terminal group, N-acetylated peptides, N-lipoic peptides, and N-palmitic peptides were analysed in order to consider the structural changes of the synthesized peptides as plasmin and urokinase inhibitors. The influence of lysine and arginine substitution in the basic KTTKS sequence was also analysed.
The first comparison was between the groups of C-terminal acids and peptide amides. Peptide activities were divided into sequences (Figure 5). The differences between the activity of acid and amide on plasmin were marginal. In each of the sequences, palmitic peptides exhibit the greatest exhibition of the enzyme. All palmitic acids and peptide amides exhibit IC50 values in the micromole range, as opposed to the other peptides, which exhibit inhibition values in the millimole range. In the case of free N-terminal peptides and their lipoic derivatives, the IC50 values are comparable. All acetylated peptides exhibit lower plasmin inhibition compared to other derivatives.
In the case of urokinase (Figure 5), it was noticed that amide peptides are weaker inhibitors compared to analogous acids. Peptides in the form of acids are the most active compounds not only towards urokinase, but also towards all the three enzymes described in this paper. In the case of the basic sequence H-Lys-Thr-Thr-Lys-Ser-OH v. H-Lys-Thr-Thr-Lys-Ser-NH2, IC50 is 0.019 mM for acid and 9.15 mM for amide (Table 1). As can be seen in Figure 3, a similar relationship is clearly visible also in the other cases. The relationship between acid-amide activity towards urokinase has previously been observed in the Department of Organic Chemistry, on the basis of inhibitors with a different sequence. A comparison was made between peptides in the form of C-terminal acid and amide with a sequence characteristic for urokinase inhibitors (Ac)H-D-Ser-Ala(Gly)-Arg-OH(NH2) [44]. Amides did not exhibit urokinase inhibition at the maximum examined concentration of 20 mM, despite the fact that they exhibited plasmin and thrombin inhibition.
In the case of thrombin exhibition, similarly to the case of plasmin, no significant differences in peptide activity resulting from the substitution of C-terminal carboxylic group for amide group were observed (Figure 5). All N-palmitic peptides are more active than others. Only in the case of a single peptide, whose sequence was Pal-KTTRS-NH2 (peptide 16, Pal-Lys-Thr-Thr-Arg-Ser-NH2; peptide 12, Pal-Lys-Thr-Thr-Arg-Ser-OH), was greater amide activity towards acid noticed, i.e., IC50 was 0.0018 mM for amide 16, 0.012 mM for acid 12 (Table 1).
In each of the eight sequences of the sequenced peptides, N-terminal acetyl group was introduced in order to test the influence of such a modification (Figure 6). The acetyl group (acetyl, Ac, -COMe, Lat. acetum) is an acetyl-type functional group derived from acetic acid. It occurs in its derivatives, e.g., acetyl chloride, acetic anhydride, acetate esters, or amides such as acetamide or acetanilide, among others. In organic synthesis it is used, e.g., as the protective group for amine and hydroxyl groups. In biological organisms acetyl groups are usually transferred from acetylo-CoA to other organic molecules [45]. Acetylo-CoA is also produced in the second stage of cellular respiration, i.e., the Krebs cycle, by the action of pyruvate dehydrogenase on pyruvic acid. Histones and other proteins are often modified through acetylation, which results in, e.g., changes in chromatin structure, making it possible for genetic transcription to occur. Acetylated organic molecules exhibit an increased ability to pass through the selectively permeable blood-brain barrier, which increases the efficacy of a given drug dose. The acetyl group in acetylsalicylic acid (aspirin) improves the drug’s efficacy compared to natural salicylic acid. Similarly, acetylation converts the natural analgesic morphine in the much stronger heroin (diacetylmorphine).
A very well-known molecule for cosmetic use containing the acetyl group, the N-terminal group in the case in question, is argireline [46]. Argireline is acetyl hexapeptide with the sequenceAc-Glu-Glu-Met-Gln-Arg-Arg-NH2. It is a fragment of SNAP-25 (which plays a role in the synaptic function of specific neuronal systems) and a substrate of botulinum 1 toxin. Argireline is used as a cosmetic ingredient to decrease the effects of aging by reducing wrinkles.
Acetylated peptides belong to the group of least active compounds of all those synthesized (Figure 6). Acetylated peptides at N-terminus are plasmin inhibitors with IC50 values from 2.24 to 9.08 mM (Table 1). The introduction of an acetylated fragment results in reduced inhibition of urokinase and thrombin activity.
Despite this clear evidence of increased activity, the synthesized N-acetylated peptides exhibit lower activity towards plasmin, urokinase, and thrombin than towards analogous sequences not containing the group in question. For, example, in the case of peptides H-Arg-Thr-Thr-Arg-Ser-OH (17) vs. Ac-Arg-Thr-Thr-Arg-Ser-OH (18), the highest reduction of activity towards plasmin was observed, with the following IC50 values: 17 N-free: 0.28 mM, while 18 N-acetylated: 8.81 mM (Table 1).
Lipoic acid (α-lipoic, LA) is an organic sulphur compound derived from octanoic acid which contains two sulphur atoms (in C6 and C8) bonded together with a disulphide bond and closed in a 5-membered ring. The carbon atom C6 is chiral, while the molecule occurs in the form of enantiomers (R)-(+)-lipoic acid (RLA), (S)-(-)-lipoic acid (SLA), and as a racemic mixture (R/S). In this paper, racemic acid was used. Lipoic acid is naturally produced in animals and plays a key role in oxidative metabolism [47,48,49,50]. It is a cofactor for at least five enzymatic systems. It also participates in the conversion of pyruvic acid to acetate and carbon dioxide and in the glycine cleavage system. Lipoic acid, as well as its reduced form, i.e., dihydrolipoic acid, may play a role in inactivation of free radicals. Moreover, they play a significant role in the regeneration of reduced forms of other antioxidants, such as vitamin C, vitamin E, glutathione, or ubiquinone. Lipoic acid has the ability to chelate metal ions (Fe2+, Cu2+, Cd2+). It is also produced and available as a dietary supplement in certain countries, where it is sold as an antioxidant. Lipoic acid does not normally occur in the skin, but it can be a good candidate for topical use: it is a small, stable molecule that can penetrate the skin effectively and may protect from harmful effects of UV radiation; it is soluble both in water and in fats.
In the case of plasmin inhibition, no significant differences were observed in the activity of N-free and N-lipoic peptides. In the case of RTTRS and RTTSK sequences, a decreased activity of lipoic peptides was observed, both by acid and amide. The introduction of lipoic residue resulted in increased activity towards plasmin only by KTTKS-OH; IC50 for N-free peptide H-Lys-Thr-Thr- Arg-Ser-OH (9) was 0.63 mM, whereas for lipoic peptide Lip-Lys-Thr-Thr-Arg-Ser-OH (13), the value was 0.24 mM. In the case of urokinase, three peptides exhibit activity higher than that of its N-free analogues: KTTRS-NH2 (15), RTTRS-NH2 (23) and RTTKS-NH2 (31). Owing to the fact that these are peptide amides, even this small increase of activity towards urokinase, compared to analogous acids, is uncommon (Figure 7).
The function of palmitic residue in cosmetics is softening, nutritional, and emulsifying [51]. Apart from the 16-carbon fragment, other residues of long-chain acids, such as myristic or lauric acid, are used. They are mostly surfactants, but their function in hair care products is also also play softening or antistatic. According to the information submitted to Food and Drug Administration (FDA) by the cosmetic industry in 2012 as part of Voluntary Cosmetic Registration Program (VCRP), over 20 palmitoyl oligopeptides, e.g.,: palmitoyl oligopeptide, palmitoyl dipeptide-7, palmitoyl tripeptide-3, palmitoyl tripeptyd-5, palmitoyl tripeptyd-8, palmitoyl-tripeptide-28, palmitoyl- tripeptide-38, palmitoyl-pentapeptide-4, or palmitoyl-hexapeptide-14 are in use [52,53].
The names of these peptides do not contain a particular sequence due to patent protection; it is, however, sometimes possible to obtain information on ingredient amino acids in literature data. For example, palmitoyl hexapeptide-36 contains, among others, aspartic acid, tryptophan, isoleucine, and phenylalanine. The palmitoyl peptides used in anti-aging creams are Pal-GHK and Pal-GQPR, ingredients of a preparation under the trade name Matrixyl 3000®. Palmitoyl pentapeptide-4 (palmitoil-pentapeptide-3 before 2006), on the other hand, whose sequence is KTTKS, studied in this paper, is a matrikine placed on the jest market in 2000, as an active ingredient of Matrixyl®, manufactured by the French producer of active cosmetics Sederma SAS (Le Perray en Yvelines Cedex, France).
Owing to the introduction of N-terminal palmitic group, the obtained peptides were the most active out of the whole series of 32 compounds (Figure 8). Each of the peptides exhibited increased activity towards all the enzymes, even the activity of amides towards urokinase increased. Peptide Pal-Lys-Thr-Thr-Lys-Ser-NH2 (8), inhibits plasmin activity at a concentration of 0.00021 mM. A peptide with such a high degree of enzyme exhibition has not yet been obtained in the Institute of Organic Chemistry. The lowest IC50 value of inhibition towards urokinase was exhibited by Pal-Arg-Thr-Thr-Lys-Ser-OH (28), 0.00048 mM, while the value of inhibition towards thrombin was 0.0018 mM for Pal-Lys-Thr-Thr-Arg-Ser-NH2 (18). Due to the presence of a long hydrocarbon chain, palmitic peptides should exhibit better skin permeability, in which case they could be used at lower concentrations but with higher activity.
In addition, modifications to the designed peptides included substitution of individual amino acids. A substitution of lysine for arginine was proposed, due to the fact that both amino acids are basic amino acids. These amino acids, however, differ in their structures as well as their roles in the body.
Arginine side chain consists of 3-carbon aliphatic straight chain ending in a guanidino group, (pKa 10.76), protonated and positively charged at physiological pH (pI 13.2). Due to the coupling between the double bond and the pairs of nitrogen atoms, the positive charge is delocalized, preventing the formation of hydrogen bonds. Lysine contains ε-amine group in the side chain, also in protonated form in biological conditions (pKa 9.74; pI 10.28).
l-Arginine and l-lysine are amino acids which, apart from protein building, participate in many metabolic processes. In humans, l-arginine may be synthesized de novo, for example from glutamine, proline, and citrulline [54]. The amino acid is essential for the healthy growth and development of children, as well as adults in conditions displaying increased catabolism, trauma, and burns. It is a neurotransmitter in the central nervous system. l-lysine belongs to the group of exogenous amino acids, which means that the body should be supplied with it together with food, as humans are unable to synthesize it [55]. An increased demand for lysine occurs in the case of slow-healing wounds, osteoporosis, HSV infection, a strict slimming or vegetarian diet, and malnutrition. In the body, lysine and arginine use the same transport system. High lysine concentrations impair arginine absorption, and vice versa. Research shows that HSV has a large demand for arginine. High levels of lysine contributes to a decrease in arginine concentration, thus inhibiting HSV growth.
Substitution of lysine amino acids for arginine did not change the synthesized compounds’ activity towards plasmin. The general activity relationship in the basic KTTKS sequence was maintained. The introduction of N-terminal acetyl group resulted in decreased inhibition of plasmin activity by the synthesized peptides. The activity of peptides containing lipoic acid residue as the N-terminal fragment is comparable with peptides with a free amine group in the N-terminal amino acid. Despite the amino acid substitution, N-palmitic peptides, regardless of whether they are C-terminal acids or amides, are the most active plasmin inhibitors (Figure 9).
A similar relationship was observed in the case of urokinase inhibition (Figure 9). Substitution of amino acids did not change the general relationship, i.e., a decreased activity of acetylated peptides, a slight increase for lipoic peptides, with the highest activity of palmitic peptides maintained. Only in the case of KTTRS sequence was increased activity of acetylated and lipoic noticed compared to KTTKS sequence.
In comparison to the basic KTTKS sequence of acids, substitution of lysine for arginine slightly increased the activity in each of the cases, except palmitic basic sequence. In the case of amides, a similar relationship was noticed, i.e., increased activity, whereas in the case of KTTRS sequence, an identical value of IC50 was noticed, as was the case with the basic sequence.
In a similar our paper on the inhibition of plasmin and urokinase, the effect of amino acid substitution on a known inhibitor of similar sequence was described. In place of alanine in the sequence Ser-Ala-Arg other aliphatic [56] or aromatic [57] amino acids were introduced. In homoleucine and neoglycine, there was a loss of enzymes inhibition, but selectivity was found for α-methylalanine and α-aminobutanoic acid. These peptides were plasmin inhibitors, but lost their ability to inhibit urokinase. It would be more interesting if it was the other way around, because urokinase is a more selective enzyme. When alanine was replaced with aromatic amino acids, there was a loss of activity relative to urokinase.
No studies on amidolytic inhibition of proteolytic enzymes by cosmetic peptides are yet known. The only in vitro enzymatic study concerned the stability of KTTKS and pal-KTTKS in skin extracts and homogenates after addition of proteolytic enzyme inhibitors [58]. Pal-KTTKS retained in different skin layers (the stratum corneum, epidermis, and dermis) and KTTKS was not detected in any skin layer. Therefore, the authors confirm that only pal-KTTKS can be used as a cosmetic with anti-wrinkle effects.
The collagen production of human dermal fibroblasts under the influence of pal-KTTKS was described by Jonas et al. [27]. Palmitoyl peptide stimulates collagen production in a concentration-dependent manner while decreasing in the number of proliferative cells in the presents of conventional collagen stimulants and basal media.
Literature data concerning similar studies of collagen biosynthesis for KTTKS-OH, PalKTTKS-OH, LipKTTKS-OH, and KTTKS-vitamin C conjugate is available. In studies performed at in this paper: KTTKS-OH (1), PalKTTKS-OH (4) and LipKTTKS-OH (3) did not exhibit fibroblast growth, which is why they were not subjected to tests of their influence on collagen biosynthesis. Chichong Lu et al. described a significant, i.e., over 150%, increase of collagen biosynthesis in the case of LipKTTKS-OH [50]. Researchers tested peptides at a single concentration of 0.5 mM, considering a maximum concentration of 5 mM as non-toxic. In our research, three concentrations were used: 10, 50, and 100 μM, the same as in the case of cytotoxicity tests. In our study, LipKTTKS-OH did not influence fibroblast growth.
Another paper provides the results of tests of collagen synthesis for KTTKS-OH, PalKTTKS-OH, and ascorbic acid residue as N-terminal [59]. The authors report an over 150% increase of collagen synthesis in the case of PalKTTKS, but no such effect for stem KTTKS. An over 400% increase in the case of KTTKS-vitamin C conjugate was noticed at a concentration of 10 μM, and as high as over 650% at a concentration of 100 μM. In our case, the range of concentrations used was also 10-50-100 μM.
Plasminogen activation system causes damage of extracellular matrix and recovery can be enhanced by inhibiting these proteinases. Therefore, matrix components, including enzymes, are a good target for skin care products, because they can improve epidermal communication and skin homeostasis, thus strengthening the defence against “skin aging”. Despite the fact that we were unable to synthesize peptides with more favourable anti-aging properties than the parent KTTKS collagen fragment, this type of research should be continued due to the necessary search for new active cosmetic ingredients.

4. Materials and Methods

4.1. Materials

Rink amide resin, chloranil, acetaldehyde, HOBt = 1-hydroxybenzotriazole, lipoic acid, palmitoyl chloride, and 1-acetylimidazole were purchased from Fluka (Schnelldorf, Germany). 2-Chlorotrityl chloride resin, TFA = trifluoroacetic acid, DIPEA = diisopropylethylamine, piperidine, TBTU = tetrafluoroborate salt of the O-(benzotriazol-1-yl)-N,N,N,N’-tetramethyluronium tetra- fluoroborate, NMP = 1-methyl-2-pyrrolidon, Fmoc-Lys(Boc)-OH (Fmoc = 9-fluorenylmethyloxy- carbonyl, Boc = benzyloxycarbonyl) were obtained from Iris Biotech GmbH (Marktrewitz, Germany). Fmoc-Arg(Pbf)-OH, Fmoc-Ser(tBu)-OH and Fmoc-Thr(tBu)-OH were products of Lipopharm.pl (Gdańsk, Poland). DCM = dichloromethane, DMF = dimethylformamide, and methanol were the products of Chempur (PiekarySlaskie, Poland). DCM was used without further purification. DMF was distilled over ninhydrin and stored under molecular sieves 4A. HPLC solvent acetonitrile was purchased from Merck (Darmstadt, Germany). Urokinase, trypsin, kallikrein and Bzl-L-Arg-pNAHCl (Bzl = benzyl) were purchased from Sigma (Schnelldorf, Germany). Plasmin, S-2444 (pyro-Glu-Gly-Arg-pNA·HCl), S-2238 (H-D-Phe-Pip-Arg-pNA), S-2251 (H-D-Val-Leu- Lys-pNA), S-2266 (H-D-Val-Leu-Arg-pNA·2HCl and S-2288 (H-D-Ile-Pro-Arg-pNA) were obtained from Chromogenix (Milano, Italy). Thrombin and phosphate buffered saline (PBS) were purchased from Lubelska Wytwórnia Szczepionek (Lublin, Poland). t-PA was obtained from Boehringer Ingelheim GmbH (Ingelheim, Germany). Fibroblasts: Normal, Human, Adult ATCC® PCS-201-012™ were purchased in ATCC, USA. Dimethylsulfoxide (DMSO), 3–(4,5-dimethylthiazol-2-yl)- 2,5-diphenyltetrazolium bromide (MTT) were purchased from Sigma Chemical Co. (St. Louis, MO, USA). Dulbecco’s minimal essential medium (DMEM), foetal bovine serum (FBS) were products of Gibco (San Diego, CA, USA). Glutamine, penicillin, and streptomycin were obtained from Quality Biologicals Inc. (Gaithersburg, MD, USA).

4.2. Peptide Synthesis

The peptides shown in Table S1 were synthesized manually using the standard Fmoc-based strategy [60]. Fmoc deprotection steps were performed with 20% (v/v) piperidine in DMF/NMP (1:1) for 3 and 8 min. separately. Peptide bonds with Fmoc amino acids were carried out through urea coupling reagent TBTU in DMF/NMP/DCM (1:1:1) of amino acid/TBTU/HOBt/resin using a molar ratio of 3:3:3:1. The reactions were monitored with the chloranil test. Cleavage from the resin was carried out with TFA/water (95/5). After 3 h stirring, the resin was filtered and washed with TFA. The combined filtrates were concentrated under reduced pressure. The crude peptide was washed with cold diethyl ether, filtered, dissolved in water and lyophilized. The Waters system (Waters Corporation, Milford, MA, USA) was used for analytical and semipreparatory HPLC (Phenomenex C18, Jupiter 90A, 4 micron, 250 × 4 mm; Phenomenex C18, Jupiter 300Å, 5 micron, 250 × 10 mm; solvents: A, 0.1% aqueous TFA; B, 0.1% TFA in acetonitrile, gradient 1% B to 99% B in A in 30 min, flow rate 1 mL/min, monitored at 220 nm). The major peak fraction was pooled and lyophilized. The molecular weight determination was performed by mass spectrometry using a Bruker Daltonics Esquire 6000 (Bruker Daltonik GmbH, Leipzig, Germany) with electrospray ionization (ESI).

4.3. Enzymatic Investigations

The determination of amidolytic activity was performed as previously described by Okada [61]. A detailed description of the method is given below: 0.2 mL of the examined peptides (0.15 M NaCl as contro), a buffer, and 0.1 mL of enzyme solution were mixed. The final peptide concentrations were: 0.2 mM, 2 mM, and 20 mM. The mixture was incubated at 37 °C for 3 min; then the synthetic substrate solution was added in the same buffer. After 20 min of incubation, the reaction was stopped by adding 0.1 mL of 50% acetic acid and the absorbance of the released p-nitroaniline was measured at 405 nm. The mean values from three independent experiments done in duplicate are presented. A method error of 5% was adopted as statistical error. IC50 value was considered as the concentration of inhibitor that reduces absorbance by 50%, compared with absorbance measured under the same conditions without an inhibitor. IC50 was calculated mathematically by extrapolation using a linear plot. IC50 values are presented in Table 1 and Table 2, and graphically in Figure 1.
The buffers and the enzyme solutions included:
  • Tris buffer—0.6 mL (pH 8.8), enzyme: urokinase (50 units/mL), synthetic substrate: pyro-Glu-Gly-Arg-pNA·HCl (0.1 mL, 3 mM);
  • Tris buffer—0.5 mL (pH 8.4), enzyme: thrombin (1 units/mL), synthetic substrate: H-D-Phe-Pip-Arg-pNA (0.2 mL, 0.75 mM);
  • Tris buffer—0.5 mL (pH 7.4), enzyme: plasmin (0.4 units/mL), synthetic substrate: H-D-Val-Leu-Lys-pNA (0.2 mL, 3 mM);
  • Borate buffer—0.5 mL (pH 7.5), enzyme: trypsin (0.4 units/mL), synthetic substrate: Bzl-L-Arg-pNA·HCl (0.2 mL, 8 mM);
  • Tris buffer—0.6 mL (pH 9.0), enzyme: kallikrein (3 units/mL), synthetic substrate: H-D-Val-Leu-Arg-pNA·2HCl (0.1 mL, 75 mM);
  • Tris buffer—0.6 mL (pH 8.4), enzyme: t-PA (167 mg/mL), synthetic substrate: H-D-Ile-Pro-Arg-pNA (0.1 mL, 10 mM)
  • Tris buffer—0.6 mL (pH 9.0), enzyme: chymotrypsin (0.4 units/mL), synthetic substrate: Suc-Phe-pNA (0.2 mL, 8 mM)

4.4. Viability of Fibroblast Cells

4.4.1. Cell Culture

These studies were performed on primary dermal fibroblasts cells. The cells were maintained in DMEM supplemented with 10% fetal bovine serum (FBS), 2 mM glutamin, 50 U/mL penicillin and 50 µm/mL streptomycin at 37 °C in a 5% CO2 incubator. For experiments, cells cultures were plated at a density of 1 × 106/well in six-well culture plates (Costar, St. Louis, MO, USA) in 2 mL of growth medium. Cells reached about 80% of confluency at day 2 were used for the assays.

4.4.2. Cell Viability Assay

Toxicity of the tested substances was determined using an MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)] assay. Palmitoyl and lipoyl peptides were dissolved in DMSO (dimethyl sulfoxide), the other peptides in DMEM, and added to the cell culture medium. Simultaneously, the same concentrations of DMSO without peptides were added to cells, serving as controls. The final peptide concentrations were: 1 μM, 10 μM, and 100 μM. After 24 h incubation, the cells cultured with the tested compounds were washed with phosphate-buffered saline (PBS) and then incubated for 4 h in 2 mL of MTT solution (5 mg/mL). After removing the medium, the cells were lysed in 200 μL of DMSO with 20 μL of Sorensen’s buffer (pH 10.5, 0.1 mol/L glycine with 0.1 mol/L NaCl). The absorbance of converted dye in living cells was measured at a wavelength of 570 nm. The viability of the tested substances was calculated as a percentage of control cells and presented in Table 3 and Figure 2. The mean values ± SD from three independent experiments done in duplicate are presented.

4.4.3. DNA Biosynthesis

To examine the effect of the studied compounds on DNA biosynthesis of fibroblast cells, they were plated in 24-well tissue culture dishes at 1 × 105 cells per well with 1 mL of growth medium. The plates were incubated after 48 h with the examined peptides and 0.5 μCi of [3H] thymidine (6.7 Ci/mmol) at 37 °C. The final peptide concentrations were: 10 μM, 50 μM, and 100 μM. After 24 h incubation, the cells were rinsed with PBS three times and twice with 5% trichloroacetic acid. To measure the radioactivity incorporated into DNA, the cells were solubilized with 1 mL of 0.1 M sodium hydroxide containing 1% SDS and an addition of scintillation liquid (9 mL) (https://www.perkinelmer.com/pl/category/scintillation-cocktails). Radioactivity was determined in a scintillation counter, i.e., Liquid Scintillation Analyzer Tri-Carb 2810 TR (Perkin Elmer, Waltham, MA USA)) with Quanto Smart TM software (Perkin Elmer). The values are presented in Table 4.

4.4.4. Collagen Biosynthesis

Fibroblasts were cultured in six-well plates until confluence. Then they were incubated for 24 h in growth medium in the absence or presence of the tested peptides and 5[3H]-proline (5 µCi/mL, 28 Ci/mM). The final peptide concentrations were: 10 μM, 50 μM and 100 μM. In accordance with the method proposed by Peterkofsky and Diegelmann [62], incorporation of the radioactive precursor into collagen was determined by digesting the proteins with purified Clostridium histolyticum collagenase. Finally, the monolayers were washed with sterile 10mM PBS, pH 7.4 four times, and cell membranes were disrupted using a sonicator. Aliquots of the cell homogenate were removed for protein measurement using the BCA™ Protein Assay Kit (Pierce, Waltham, MA USA). The results are shown as combined values for cell plus medium fractions. The values are presented in Table 5.

5. Conclusions

The purpose of the paper was to find the structure-activity relationship of novel analogues of KTTKS. The enzymatic activity of plasmin, urokinase and thrombin, the viability of fibroblasts, and DNA and collagen biosynthesis were evaluated. The results showed that the most active plasmin inhibitors were palmitoyl peptides. No effects of lysine modification on arginine in the synthesized peptides were found. Peptides showed no cytotoxicity on fibroblasts. Three of them did not show a correlation between the concentration increase in collagen biosynthesis and DNA.

Supplementary Materials

The following are available online, Table S1: Sequences and physico-chemical parameters of synthesized peptides 1–32.

Author Contributions

Conceptualization, A.M.; Investigation, U.T., P.U., I.B., A.S. and I.Z.; Writing—review & editing, A.M.

Funding

This research was funded by Medical University of Białystok, from a subsidy of the Minister of Science and Higher Education, Poland.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Baumann, L. Skin ageing and its treatment. J. Pathol. 2007, 211, 241–251. [Google Scholar] [CrossRef] [PubMed]
  2. Farage, M.A.; Miller, K.W.; Elsner, P.; Maibach, H.I. Intrinsic and extrinsic factors in skin ageing: A review. Int. J. Cosm. Sci. 2008, 30, 87–95. [Google Scholar] [CrossRef] [PubMed]
  3. Maquart, F.X.; Bellon, G.; Pasco, S.; Monboisse, J.C. Matrikines in the regulation of extracellular matrix degradation. Biochimie 2005, 87, 353–360. [Google Scholar] [CrossRef] [PubMed]
  4. Aldag, C.; Nogueira Teixeira, D.; Leventhal, P.S. Skin rejuvenation using cosmetic products containing growth factors, cytokines, and matrikines: A review of the literature. Clin. Cosmet. Investig. Dermatol. 2016, 9, 411–419. [Google Scholar] [CrossRef]
  5. Reddy, B.; Jow, T.; Hantash, B.M. Bioactive oligopeptides in dermatology: Part, I. Exp. Dermatol. 2012, 21, 569–575. [Google Scholar] [CrossRef]
  6. Malerich, S.; Berson, D. Next Generation Cosmeceuticals. Dermatol. Clin. 2014, 32, 13–21. [Google Scholar] [CrossRef]
  7. Maquart, F.X.; Pasco, S.; Ramont, L.; Hornebeck, W.; Monboisse, J.C. An introduction to matrikines: Extracellular matrix-derived peptides which regulate cell activity: Implication in tumor invasion. Crit. Rev. Oncol. Hematol. 2004, 49, 199–202. [Google Scholar] [CrossRef]
  8. Tran, K.T.; Lamb, P.; Deng, J.S. Matrikines and matricryptins: Implications for cutaneous cancers and skin repair. J. Dermatol. Sci 2005, 40, 11–20. [Google Scholar] [CrossRef]
  9. Wells, J.M.; Gaggar, A.; Blalock, J.E. MMP generated matrikines. Matrix Biol. 2015, 44–46, 122–129. [Google Scholar] [CrossRef]
  10. Ricard-Blum, S.; Salza, R. Matricryptins and matrikines: Biologically active fragments of the extracellular matrix. Exp. Derm. 2014, 23, 457–463. [Google Scholar] [CrossRef]
  11. Senyürek, I.; Klein, G.; Kalbacher, H.; Deeg, M.; Schittek, B. Peptides derived from the human laminin α4 and α5 chains exhibit antimicrobial activity. Peptides 2010, 31, 468–1472. [Google Scholar]
  12. Wang, H.; Chen, Y.; Lu, X.; Liu, G.; Fu, Y.; Luo, Y. Endostatin Prevents Dietary-Induced Obesity by Inhibiting Adipogenesis and Angiogenesis. Diabetes 2015, 64, 2442–2456. [Google Scholar] [CrossRef] [Green Version]
  13. Blaise, S.; Romier, B.; Kawecki, C.; Ghirardi, M.; Rabenoelina, F.; Baud, S.; Duca, L.; Maurice, P.; Heinz, A.; Schmelzer, C.E.H.; et al. Elastin-derived peptides are new regulators of insulin resistance development in mice diabetes. Diabetes 2013, 62, 3807–3816. [Google Scholar] [CrossRef] [PubMed]
  14. Zhao, Y.; Gu, X.; Zhang, N.; Kolonin, M.G.; An, Z.; Sun, K. Divergent functions of endotrophin on different cell populations in adipose tissue. Am. J. Physiol. Endocrinol. Metab. 2016, 311, E952–E963. [Google Scholar] [CrossRef] [PubMed]
  15. Sun, K.; Park, J.; Kim, M.; Scherer, P.E. Endotrophin, a multifaceted player in metabolic dysregulation and cancer progression, is a predictive biomarker for the response to PPARγ agonist treatment. Diabetologia 2017, 60, 24–29. [Google Scholar] [CrossRef]
  16. Briknarová, K.; Åkerman, M.E.; Hoyt, D.W.; Ruoslahti, E.; Ely, K.R. Anastellin, an FN3 fragment with fibronectin polymerization activity, resembles amyloid fibril precursors. J. Mol. Biol. 2003, 332, 205–215. [Google Scholar] [CrossRef]
  17. You, R.; Klein, R.M.; McKeown-Longo, P.J. Regulation of p38 MAP kinase by anastellin is independent of anastellin’s effect on matrix fibronectin. Matrix Biol. 2009, 28, 101–109. [Google Scholar] [CrossRef]
  18. Pickart, L.; Margolina, A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int. J. Mol. Sci. 2018, 19, 1987. [Google Scholar] [CrossRef]
  19. Pickart, L. The human tri-peptide GHK and tissue remodeling. J. Biomater. Sci. Polym. Edn. 2008, 19, 969–988. [Google Scholar] [CrossRef] [Green Version]
  20. Baud, S.; Duca, L.; Bochicchio, B.; Brassart, B.; Belloy, N.; Pepe, A.; Dauchez, M.; Martiny, L.; Debelle, L. Elastin peptides in aging and pathological conditions. Biomol. Concepts 2013, 4, 65–76. [Google Scholar] [CrossRef]
  21. Rousselle, P.; Carulli, S.; Chajra, H.; Dayan, G.; Pin, D.; Herbage, B. The syndecan binding sequence KKLRIKSKEK in laminin α3 LG4 domain promotes epidermal repair. Eur. J. Dermatol. 2013. [Google Scholar] [CrossRef]
  22. Malinda, K.M.; Wysocki, A.B.; Koblinski, J.E.; Kleinman, H.K.; Ponce, M.L. Angiogenic laminin-derived peptides stimulate wound healing. Int. J. Biochem. Cell Biol. 2008, 40, 2771–2780. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Ghazi, K.; Deng-Pichon, U.; Warnet, J.M.; Rat, P. Hyaluronan fragments improve wound healing on in vitro cutaneous model through P2 × 7 purinoreceptor basal activation: Role of molecular weight. PLoS ONE 2012, 7, e48351. [Google Scholar] [CrossRef]
  24. D’Agostino, A.; Stellavato, A.; Busico, T.; Papa, A.; Tirino, V.; Papaccio, G.; La Gatta, A.; De Rosa, M.; Schiraldi, C. In vitro analysis of the effects on wound healing of high- and low-molecular weight chains of hyaluronan and their hybrid H-HA/L-HA complexes. BMC Cell Biol. 2015, 16, 19–34. [Google Scholar]
  25. Gorouhi, F.; Maibach, H.I. Role of topical peptides in preventing or treating aged skin. Int. J. Cosmet. Sci. 2009, 31, 327–345. [Google Scholar] [CrossRef] [PubMed]
  26. Abu Samah, N.H.; Heard, C.M. Topically applied KTTKS: A review. Int. J. Cosmet. Sci. 2011, 33, 483–490. [Google Scholar] [CrossRef]
  27. Jones, R.R.; Castelletto, V.; Connon, C.J.; Hamley, I.W. Collagen stimulating effect of peptide amphiphile C16–KTTKS on human fibroblasts. Mol. Pharm. 2013, 10, 1063–1069. [Google Scholar] [CrossRef] [PubMed]
  28. Werner, S.; Krieg, T.; Smola, H. Keratinocyte—Fibroblast interaction in wound healing. J. Investig. Dermatol. 2007, 172, 998–1008. [Google Scholar] [CrossRef] [PubMed]
  29. Rawlings, A.V. The stratum corneum and aging. In Textbook of Aging Skin; Farage, M.A., Miller, K.W., Maibach, H.I., Eds.; Springer: Berlin/Heidelberg, Germany, 2010. [Google Scholar] [CrossRef]
  30. Suzuki, Y.; Nomura, J.; Koyama, J.; Horii, I. The role of proteases in stratum corneum: Involvement in stratum corneum desquamation. Arch. Dermatol. Res. 1994, 286, 249–253. [Google Scholar] [CrossRef]
  31. Harding, C.R.; Watkinson, A.; Rawlings, A.V.; Scott, I.R. Dry skin, moisturization and corneodesmolysis. Int. J. Cosmet. Sci. 2000, 22, 21–52. [Google Scholar] [CrossRef] [PubMed]
  32. Amano, S. Characterization and mechanisms of photoageing- related changes in skin. Damages of basement membrane and dermal structures. Exp. Dermatol. 2016, 25 (Suppl. 3), 14–19. [Google Scholar] [CrossRef] [PubMed]
  33. Rawlings, A.V.; Voegeli, R. Stratum corneum proteases and dry skin conditions. Cell Tissue Res. 2013, 351, 217–235. [Google Scholar] [CrossRef] [PubMed]
  34. Voegeli, R.; Rawlings, A.V.; Doppler, S.; Heiland, J.; Schreier, T. Profiling of serine protease activities in human stratum corneum and detection of a stratum corneum tryptase-like enzyme. Int. J. Cosmet. Sci. 2007, 29, 191–200. [Google Scholar] [CrossRef] [PubMed]
  35. Katsuta, Y.; Yoshida, Y.; Kawai, E.; Kohno, Y.; Kitamura, K. Urokinase-type plasminogen activator is activated in stratum corneum after barrier disruption. J. Dermatol. Sci. 2003, 32, 55–57. [Google Scholar] [CrossRef]
  36. Tagami, H. Location-related differences in structure and function of the stratum corneum with special emphasis on those of the facial skin. Int. J. Cosmet. Sci. 2008, 30, 435–442. [Google Scholar] [CrossRef]
  37. Voegeli, R.; Rawlings, A.V.; Doppler, S.; Schreier, T. Increased basal transepidermal water loss leads to elevation of some but not all stratum corneum serine proteases. Int. J. Cosmet. Sci. 2008, 30, 435–442. [Google Scholar] [CrossRef]
  38. Poojary, S.; Minni, K. Tranexamic Acid in Melasma: A Review. Pigment. Disord. 2015, 2, 228–232. [Google Scholar] [CrossRef]
  39. Taraz, M.; Niknam, S.; Ehsani, A.H. Tranexamic acid in treatment of melasma: A comprehensive review of clinical studies. Dermatol. Ther. 2017, 30, e12465. [Google Scholar] [CrossRef]
  40. Denda, M.; Kitamura, K.; Elias, P.M.; Feingold, K.R. Trans-4-(Aminomethyl)cyclohexane Carboxylic Acid (T-AMCHA), an Anti-Fibrinolytic Agent, Accelerates Barrier Recovery and Prevents the Epidermal Hyperplasia Induced by Epidermal Injury in Hairless Mice and Humans. J. Investig. Dermatol. 1997, 109, 84–90. [Google Scholar] [CrossRef]
  41. Vávrová, K.; Hrabálek, A.; Doležal, P.; Holas, T.; Klimentová, J. Biodegradable derivatives of tranexamic acid as transdermal permeation enhancers. J. Control. Release 2005, 104, 41–49. [Google Scholar] [CrossRef]
  42. Voegeli, R.; Wikstroem, P.; Campiche, R.; Steinmetzer, T.; Jackson, E.; Gempeler, M.; Imfeld, D.; Rawlings, A.V. The effects of benzylsulfonyl-D-Ser-homoPhe-(4-amidino-benzylamide), a dual plasmin and urokinase inhibitor, on facial skin barrier function in subjects with sensitive skin. Int. J. Cosmet. Sci. 2017, 39, 109–120. [Google Scholar] [CrossRef] [PubMed]
  43. Aisina, R.B.; Mukhametova, L.I. Structure and function of plasminogen/plasmin system. Russ. J. Bioorg. Chem. 2014, 40, 590–605. [Google Scholar] [CrossRef]
  44. Markowska, A.; Bruzgo, I.; Midura-Nowaczek, K. Effects of tripeptides on the amidolytic activities of urokinase, thrombin, plasmin and trypsin. Int. J. Pept. Res. 2008, 14, 215–218. [Google Scholar] [CrossRef]
  45. GuanK, L.; Xiong, Y. Regulation of intermediary metabolism by protein acetylation. Trends Biochem. Sci. 2011, 36, 108–116. [Google Scholar] [CrossRef] [Green Version]
  46. Lim, S.H.; Sun, Y.; Madanagopal, T.T.; Rosa, V.; Kang, L. Enhanced Skin Permeation of anti-wrinkle peptides via molecular modification. Sci. Rep. 2018, 8, 1596. [Google Scholar] [CrossRef]
  47. Rochette, L.; Ghibu, S.; Muresan, A.; Vergely, C. Alpha-lipoic acid: Molecular mechanisms and therapeutic potential in diabetes. Can. J. Physiol. Pharm. 2015, 93, 1021–1027. [Google Scholar] [CrossRef]
  48. Ho, Y.S.; Lai, C.S.; Liu, H.I.; Hoc, S.Y.; Tai, C.; Pan, M.H.; Wang, Y.J. Dihydrolipoic acid inhibits skin tumor promotion through anti-inflammation and anti-oxidation. Biochem. Pharm. 2007, 73, 1786–1795. [Google Scholar] [CrossRef]
  49. Moini, H.; Packer, L.; Saris, N.E.L. Antioxidant and prooxidant activities of α-lipoic acid and dihydrolipoic acid. Toxicol. Appl. Pharm. 2002, 182, 84–90. [Google Scholar] [CrossRef]
  50. Chichong, L.; Kim, B.M.; Lee, D.; Lee, M.H.; Kim, J.H.; Pyo, H.B.; Chai, K.Y. Synthesis of lipoic acid–peptide conjugates and their effect on collagen and melanogenesis. Eur. J. Med. Chem. 2013, 69, 449–454. [Google Scholar]
  51. Zhang, L.; Bulaj, G. Converting peptides into drug leads by lipidation. Curr. Med. Chem. 2012, 19, 1602–1618. [Google Scholar] [CrossRef]
  52. Safety Assessment of Palmitoyl Oligopeptides as Used in Cosmetics, Cosmetic Ingredient Review. Available online: https://www.cir-safety.org/sites/default/files/palmit072012slr.pdf (accessed on 11 October 2019).
  53. Schagen, S.K. Topical Peptide Treatments with Effective Anti-Aging Results. Cosmetics 2017, 4, 16. [Google Scholar] [CrossRef]
  54. Albaugh, V.L.; Barbul, A. Arginine. Ref. Modul. Life Sci. 2017. [Google Scholar] [CrossRef]
  55. Singh, M.; Rao, D.M.; Pande, S.; Battu, S.; Mahalakshmi, K.; Dutt, K.R.; Ramesh, M. Medicinal uses of l-lysine: Past and future. Int. J. Res. Pharm. Sci. 2011, 2, 637–642. [Google Scholar]
  56. Markowska, A.; Bruzgo, I.; Miltyk, W.; Midura-Nowaczek, K. Tripeptides with C-terminal arginine as potential inhibitors of urokinase. Int. J. Pept. Res. Ther. 2011, 17, 47–52. [Google Scholar] [CrossRef]
  57. Markowska, A.; Bruzgo, M.; Surażyński, A.; Midura-Nowaczek, K. Tripeptides with non-code amino acids as potential serine proteases inhibitors. J. Enzym. Inhib. Med. Chem. 2013, 28, 639–643. [Google Scholar] [CrossRef] [PubMed]
  58. Choi, Y.L.; Park, E.J.; Kim, E.; Na, D.H.; Shin, Y.H. Dermal stability and in vitro skin permeation of collagen pentapeptides (KTTKS and palmitoyl-KTTKS). Biomol. Ther. 2014, 22, 321–327. [Google Scholar] [CrossRef]
  59. Choi, H.I.; Kim, H.J.; Park, J.I.; Shin, E.H.; Kim, D.W.; Kim, S.S. Design and efficient synthesis of novel ascorbyl conjugated peptide with high collagen biosynthesis stimulating effects. Bioorg. Med. Chem. Lett. 2009, 19, 2079–2082. [Google Scholar] [CrossRef]
  60. Chan, W.C.; White, P.D. Fmoc Solid Phase Peptide Synthesis: A Practical Approach, 1st ed.; Oxford University Press: Oxford, UK, 2000. [Google Scholar]
  61. Okada, Y.; Tsuda, Y.; Teno, N.; Wanaka, K.; Bohgaki, M.; Hijikata-Okunomiya, A.; Naito, T.; Okamoto, S. Synthesis of active center-directed peptide inhibitors of plasmin. Chem. Pharm. Bull. 1988, 36, 1289–1297. [Google Scholar] [CrossRef]
  62. Peterkofsky, B.; Diegelmann, R. Use of a mixture of proteinase-free collagenases for the specific assay of radioactive collagen in the presence of other proteins. Biochemistry 1971, 10, 988–994. [Google Scholar] [CrossRef]
Sample Availability: Samples of the compounds are available from the authors.
Molecules 24 03698 g001 550
Figure 1. Inhibition of plasmin, urokinase, and thrombin by 1–32 peptides presented as -logIC50.
Figure 1. Inhibition of plasmin, urokinase, and thrombin by 1–32 peptides presented as -logIC50.
Molecules 24 03698 g001
Molecules 24 03698 g002 550
Figure 2. Viability of fibroblast cells treated for 24 h with different concentrations of the tested peptides 1–32 (Table 3).
Figure 2. Viability of fibroblast cells treated for 24 h with different concentrations of the tested peptides 1–32 (Table 3).
Molecules 24 03698 g002
Molecules 24 03698 g003 550
Figure 3. Influence of the synthesized peptides 13, 14 and 26 on DNA biosynthesis.
Figure 3. Influence of the synthesized peptides 13, 14 and 26 on DNA biosynthesis.
Molecules 24 03698 g003
Molecules 24 03698 g004 550
Figure 4. Influence of the synthetized peptides 13, 14 and 26 on collagen biosynthesis.
Figure 4. Influence of the synthetized peptides 13, 14 and 26 on collagen biosynthesis.
Molecules 24 03698 g004
Molecules 24 03698 g005 550
Figure 5. Influence of peptides in the form of C-terminal acids and amides on plasmin, urokinase and thrombin activity. Inhibition values in the form of -logIC50 from Table 3.
Figure 5. Influence of peptides in the form of C-terminal acids and amides on plasmin, urokinase and thrombin activity. Inhibition values in the form of -logIC50 from Table 3.
Molecules 24 03698 g005
Molecules 24 03698 g006 550
Figure 6. Influence of the introduction of N-terminal acetyl group in the synthetized peptides on plasmin, urokinase and thrombin inhibition. Inhibition values in the form of -logIC50 from Table 3.
Figure 6. Influence of the introduction of N-terminal acetyl group in the synthetized peptides on plasmin, urokinase and thrombin inhibition. Inhibition values in the form of -logIC50 from Table 3.
Molecules 24 03698 g006
Molecules 24 03698 g007 550
Figure 7. Influence of the introduction of N-terminal lipoic group in the synthetized peptides on plasmin, urokinase, thrombin inhibition. Inhibition values in the form of -logIC50 from Table 2.
Figure 7. Influence of the introduction of N-terminal lipoic group in the synthetized peptides on plasmin, urokinase, thrombin inhibition. Inhibition values in the form of -logIC50 from Table 2.
Molecules 24 03698 g007
Molecules 24 03698 g008 550
Figure 8. Influence of the introduction of N-terminal palmitic group in the synthetized peptides on plasmin, urokinase and thrombin inhibition. Inhibition values in the form of -logIC50 from Table 2.
Figure 8. Influence of the introduction of N-terminal palmitic group in the synthetized peptides on plasmin, urokinase and thrombin inhibition. Inhibition values in the form of -logIC50 from Table 2.
Molecules 24 03698 g008
Molecules 24 03698 g009 550
Figure 9. Influence of the synthetized peptides on plasmin, urokinase and thrombin activity with substitution of amino acids in sequences taken into account. Values in the form of -logIC50.
Figure 9. Influence of the synthetized peptides on plasmin, urokinase and thrombin activity with substitution of amino acids in sequences taken into account. Values in the form of -logIC50.
Molecules 24 03698 g009
Table
Table 1. Influence of the tested compounds on amidolytic activity of plasmin, urokinase, and thrombin in the form of IC50 [mM] (peptides most active as enzyme inhibitors are marked grey).
Table 1. Influence of the tested compounds on amidolytic activity of plasmin, urokinase, and thrombin in the form of IC50 [mM] (peptides most active as enzyme inhibitors are marked grey).
NoPeptideIC50 [mM]
PlasminUrokinaseThrombin
1KTTKSOH0.28 ± 0.0140.019 ± 0.000947.81 ± 0.39
2AcKTTKSOH2.78 ± 0.143.88 ± 0.192.20 ± 0.11
3LipKTTKSOH0.47 ± 0.0230.024 ± 0.001212.83 ± 0.64
4PalKTTKSOH0.00071 ± 0.0000350.00086 ± 0.0000430.0018 ± 0.00009
5KTTKSNH20.53 ± 0.0269.15 ± 0.467.04 ± 0.35
6AcKTTKSNH22.92 ± 0.1561.76 ± 3.093.25 ± 0.16
7LipKTTKSNH20.58 ± 0.02915.07 ± 0.7511.70 ± 0.58
8PalKTTKSNH20.00021 ± 0.0000103.12 ± 0.160.046 ± 0.0023
9KTTRSOH0.63 ± 0.0310.011 ± 0.000544.01 ± 0.20
10AcKTTRSOH2.24 ± 0.114.82 ± 0.0412.89 ± 0.14
11LipKTTRSOH0.24 ± 0.0120.019 ± 0.0009310.94 ± 0.54
12PalKTTRSOH0.00078 ± 0.0000390.00080 ± 0.000040.012 ± 0.00058
13KTTRSNH20.72 ± 0.03617.62 ± 0.884.65 ± 0.23265
14AcKTTRSNH25.34 ± 0.275.56 ± 0.282.95 ± 0.15
15LipKTTRSNH20.69 ± 0.0353.47 ± 0.174.11 ± 0.21
16PalKTTRSNH20.00086 ± 0.0000432.37 ± 0.120.0018 ± 0.00009
17RTTRSOH0.28 ± 0.0140.015 ± 0.000763.89 ± 0.19
18AcRTTRSOH8.81 ± 0.443.24 ± 0.163.12 ± 0.16
19LipRTTRSOH1.014 ± 0.0510.022 ± 0.00111.84 ± 0.092
20PalRTTRSOH0.00055 ± 0.0000270.00049 ± 0.0000240.03004 ± 0.0015
21RTTRSNH20.44 ± 0.02211.97 ± 0.592.93 ± 0.14
22AcRTTRSNH29.08 ± 0.4524.96 ± 1.251.47 ± 0.074
23LipRTTRSNH21.89 ± 0.0944.67 ± 0.232.36 ± 0.12
24PalRTTRSNH20.00042 ± 0.0000210.26 ± 0.0130.041 ± 0.0020
25RTTKSOH0.54 ± 0.0270.0106 ± 0.000532.51 ± 0.13
26AcRTTKSOH5.45 ± 0.272.36 ± 0.120.81 ± 0.041
27LipRTTKSOH2.12 ± 0.110.097 ± 0.00494.23 ± 0.12
28PalRTTKSOH0.00067 ± 0.0000330.00048 ± 0.0000240.0021 ± 0.00011
29RTTKSNH20.30 ± 0.0157.95 ± 0.402.43 ± 0.12
30AcRTTKSNH25.00 ± 0.2512.07 ± 0.601.59 ± 0.080
31LipRTTKSNH23.23 ± 0.164.57 ± 0.235.59 ± 0.28
32PalRTTKSNH20.00045 ± 0.0000230.49 ± 0.0240.0306 ± 0.0015
Table
Table 2. Influence of the tested compounds on amidolytic activity of plasmin, urokinase, and thrombin in the form -logIC50 (peptides most active as enzyme inhibitors are marked grey).
Table 2. Influence of the tested compounds on amidolytic activity of plasmin, urokinase, and thrombin in the form -logIC50 (peptides most active as enzyme inhibitors are marked grey).
NoCompound-logIC50
PlasminUrokinaseThrombin
1KTTKSOH3.55 ± 0.184.72 ± 0.242.11 ± 0.11
2AcKTTKSOH2.56 ± 0.132.41 ± 0.122.66 ± 0.13
3LipKTTKSOH3.33 ± 0.174.63 ± 0.231.89 ± 0.09
4PalKTTKSOH6.15 ± 0.316.06 ± 0.305.75 ± 0.29
5KTTKSNH23.28 ± 0.162.04 ± 0.102.15 ± 0.11
6AcKTTKSNH22.53 ± 0.131.21 ± 0.062.49 ± 0.12
7LipKTTKSNH23.24 ± 0.161.82 ± 0.091.93 ± 0.10
8PalKTTKSNH26.67 ± 0.332.51 ± 0.134.34 ± 0.22
9KTTRSOH3.20 ± 0.164.96 ± 0.252.40 ± 0.12
10AcKTTRSOH2.65 ± 0.132.32 ± 0.122.54 ± 0.13
11LipKTTRSOH3.61 ± 0.184.73 ± 0.241.96 ± 0.10
12PalKTTRSOH6.11 ± 0.316.10 ± 0.304.93 ± 0.25
13KTTRSNH23.15 ± 0.161.75 ± 0.092.33 ± 0.12
14AcKTTRSNH22.27 ± 0.112.25 ± 0.112.53 ± 0.13
15LipKTTRSNH23.16 ± 0.162.46 ± 0.122.39 ± 0.12
16PalKTTRSNH26.07 ± 0.302.63 ± 0.135.75 ± 0.29
17RTTRSOH3.54 ± 0.184.82 ± 0.242.41 ± 0.12
18AcRTTRSOH2.05 ± 0.102.49 ± 0.122.51 ± 0.13
19LipRTTRSOH2.99 ± 0.154.66 ± 0.232.74 ± 0.14
20PalRTTRSOH6.26 ± 0.316.31 ± 0.324.52 ± 0.23
21RTTRSNH23.36 ± 0.171.92 ± 0.102.53 ± 0.13
22AcRTTRSNH22.04 ± 0.101.60 ± 0.082.83 ± 0.14
23LipRTTRSNH22.72 ± 0.142.33 ± 0.122.63 ± 0.13
24PalRTTRSNH26.38 ± 0.323.59 ± 0.184.39 ± 0.22
25RTTKSOH3.27 ± 0.164.97 ± 0.252.60 ± 0.13
26AcRTTKSOH2.26 ± 0.112.63 ± 0.133.09 ± 0.15
27LipRTTKSOH2.67 ± 0.134.01 ± 0.202.37 ± 0.12
28PalRTTKSOH6.18 ± 0.316.32 ± 0.325.67 ± 0.28
29RTTKSNH23.51 ± 0.182.10 ± 0.102.61 ± 0.13
30AcRTTKSNH22.30 ± 0.121.92 ± 0.102.80 ± 0.14
31LipRTTKSNH22.49 ± 0.122.34 ± 0.122.25 ± 0.11
32PalRTTKSNH26.34 ± 0.323.31 ± 0.174.51 ± 0.23
Table
Table 3. Viability of fibroblast cells treated for 24 h with different concentrations of the tested peptides 1–32 (% of Control ± 2). Peptides exhibiting a significant cell growth effect are marked grey.
Table 3. Viability of fibroblast cells treated for 24 h with different concentrations of the tested peptides 1–32 (% of Control ± 2). Peptides exhibiting a significant cell growth effect are marked grey.
Synthesized Peptides
Concentration
[µmol/L]		12345678910111213141516
1959894979197979693104102103121112112104
10828881919188898310310010598139135122114
10080828185100868783101949899145150115115
Synthesized Peptides
Concentration
[µmol/L]		17181920212223242526272829303132
1898879908410289949711210510410195107104
109910381909499791048713791103111105112113
10011510790103103101889710915080106110101117118
Control without peptides, viability 100%.
Table
Table 4. DNA biosynthesis (% of Control ± 2).
Table 4. DNA biosynthesis (% of Control ± 2).
Peptides
Concentration
[µmol/L]		131426
1084114126
508696112
10074127128
Table
Table 5. Collagen biosynthesis (% of Control ± 2).
Table 5. Collagen biosynthesis (% of Control ± 2).
Peptides
Concentration
[µmol/L]		131426
1010105166
5015517177
10049157108

Share and Cite

MDPI and ACS Style

Tałałaj, U.; Uścinowicz, P.; Bruzgo, I.; Surażyński, A.; Zaręba, I.; Markowska, A. The Effects of a Novel Series of KTTKS Analogues on Cytotoxicity and Proteolytic Activity. Molecules 2019, 24, 3698. https://doi.org/10.3390/molecules24203698

AMA Style

Tałałaj U, Uścinowicz P, Bruzgo I, Surażyński A, Zaręba I, Markowska A. The Effects of a Novel Series of KTTKS Analogues on Cytotoxicity and Proteolytic Activity. Molecules. 2019; 24(20):3698. https://doi.org/10.3390/molecules24203698

Chicago/Turabian Style

Tałałaj, Urszula, Paulina Uścinowicz, Irena Bruzgo, Arkadiusz Surażyński, Ilona Zaręba, and Agnieszka Markowska. 2019. "The Effects of a Novel Series of KTTKS Analogues on Cytotoxicity and Proteolytic Activity" Molecules 24, no. 20: 3698. https://doi.org/10.3390/molecules24203698

Article Metrics

Back to TopTop